Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Related Research units
Abstract
A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL).
Bibliographical data
| Original language | German |
|---|---|
| Article number | 10 |
| ISSN | 0923-7534 |
| Publication status | Published - 2010 |
| pubmed | 20335368 |
|---|
